Mission of AIM with Immunotherapy
AIM with Immunotherapy seeks to educate medical professionals on the treatments that use the immune system to fight cancer and to provide tools and resources to manage immune-related adverse events (irAEs), all to help patients receive the best possible outcomes.
Both in the U.S. and on a global level, we provide comprehensive, easy-to-access pan-tumor resources for healthcare professionals and their patients.
AIM with Immunotherapy broadly defines immunotherapeutic agents as:
- Those that seek to enhance or suppress the immune system response,
- Regenerate immune recognition of foreign antigens,
- Interfere with checkpoint controls,
- And/or are comprised of molecules stemming from the natural immunology.
These agents currently include antibody-drug conjugates, bispecific antibodies, CAR T-cell therapy, cytokines/immune system modulators, immune checkpoint inhibitors, monoclonal antibodies, tumor-infiltrating lymphocytes, and vaccines. There are likely to be other agents created to fight cancer that will also fit under the broad description of immunotherapy.
Education about Immunotherapies
There is a need for knowledge transfer from experts within the oncology academic centers and research community to community-based practitioners and clinicians now utilizing immune-based therapies across many different tumor types. Each year, new and innovative immunotherapy agents receive FDA approval. This site is dedicated to updating professionals about these topics.
Provider Recognition and Management of Immune-Related Adverse Effects (irAEs)
As immune checkpoint inhibitors are employed in a wider array of tumor types, a range of irAEs are being recognized. Some of these toxicities can be difficult to diagnose, complex to manage, and potentially persistent throughout a patient’s life. This site is dedicated to engaging healthcare providers to optimally address irAEs, with a focus on contextual issues within the tumor types.
Providing Resources for Providers to Use With Their Patients
This effort is designed to educate providers and patients receiving cancer immunotherapy. Patient education will allow patients to become proactive members of the oncology team in terms of irAE recognition and management. With the achievement of this goal, AIM with Immunotherapy should help improve therapeutic outcomes for patients receiving immunotherapy for the treatment of their cancer.